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OBJECTIVE: The aims of this study were: (1) to evaluate
the burden of influenza in terms of its impact on an indi-
vidual’s normal daily activities (including ability to work);
(2) to evaluate the beneficial effect of treatment with Osel-
tamivir on activity.
METHODS: The impact of influenza on the individual
was assessed by seven symptoms and a set of well-being
indicators. These indicators include the self-rated param-
eters for general health, sleep quality, overall level of ac-
tivity and paid work activity. This analysis is based on
pooled data derived from two double-blind, randomized
and stratified, placebo-controlled multi-centre studies
conducted in the winter season 1997/1998.
RESULTS: In the intent to treat infected population (ITTI),
median return to normal levels of daily activity was acceler-
ated by 2.7 days or by 27% when the patient received Osel-
tamivir instead of standard treatment (178.8 hours, 95%
CI 156.8 to 203.2, p  .0001 for Oseltamivir 75 mg com-
pared with 243.7 hours, 95% CI 206.5 to 276.2 for stan-
dard treatment). The greatest treatment effect was seen in
the population of patients eligible for work (ITTI, full,
part-time workers). In this population, median return to
normal levels of daily activity was accelerated by 4.5 days,
or an improvement of 41%. In this population, effects of
treatment also translated into a gain in number of hours
worked. Thus at day 7, the treatment effect on cumulative
hours worked was between 4.716 h (95% CI 2.32–7.11,
p  .001) and 3.755 h (95% CI 0.54–6.97, p  0.022) in
the 2 studies. This difference was detectable and statisti-
cally significant from day 4 of the illness onwards.
CONCLUSION: The impact of influenza on the daily ac-
tivities of those affected is large and should not be dis-
missed as trivial. Treatment with Oseltamivir has a sig-
nificant beneficial effect, particularly in the working
population.
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OBJECTIVE: Among persons with sexually transmitted
diseases (STD), the proportion that is also infected with
HIV is higher than in the general population. Since many
cases of HIV infection remain undetected during the as-
ymptomatic stage, HIV-infected patients are likely to per-
form the same sexual behavior as before and put partners
at risk of infection. Detection of asymptomatic HIV in-
fection will enable the person to protect partners by
changing sexual behavior, reducing the number of sec-
ondary transmissions. Therefore, HIV screening in clinics
for sexually transmitted diseases (STD-clinic) is a poten-
tial tool to control the epidemic. In our analysis we esti-
mate the cost-effectiveness of universal HIV screening of
patients attending a STD-clinic in Amsterdam.
METHODS: Cost-effectiveness analysis. A Bernoulli model
for the secondary transmission of HIV was linked with
epidemiological data on infection with HIV and other
STD in patients attending a STD-clinic in Amsterdam
from 1991 to 1997. This gave estimates of the number
of secondary HIV infections caused by visitors to the
STD-clinic. Combined with data on the health and mon-
etary benefits of averting HIV-infection and costs of
HIV-screening, we assessed the cost-effectiveness of HIV-
screening of visitors to the STD-clinic. Standard techniques
for cost-effectiveness analysis were used, and both costs
and life years gained were discounted at 4%.
RESULTS: Increased risk for HIV infection was found in
STD clinic attenders infected with another STD. (Odds
ratio: 2.07) The risk differed for different STDs, with the
highest odds ratios for syphilis and gonorrhea. Screening
of all attenders was estimated at a net cost of €82,552 per
secondary infection averted, with a cost-effectiveness ratio
of €1637 per life year gained (LYG). The cost-effective-
ness ratio ranges between €680 and €9335 per LYG, de-
pending on key parameters in the model.
CONCLUSION: Compared to other interventions in in-
fectious disease control in the Netherlands, this interven-
tion has an acceptable cost-effectiveness ratio.
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OBJECTIVE: To incorporate the cost of drug compliance
into existing estimates of the cost of treating HIV/AIDS
in Africa.
METHODS: Recent reports have estimated that the cost
of treating the AIDS epidemic in Africa could range be-
tween $1 billion and $10 billion dollars. These studies,
however, fail to account accurately for the impact of fail-
ing to comply with triple-combination highly active anti-
retroviral therapy for HIV/AIDS. Since non-compliance
has been demonstrated to have a significant effect on vi-
rological failure, and it is recognized that virological fail-
ure results in higher resource utilization, we incorporated
the link between compliance and resource utilization in
our analysis. As a base case, we used published estimates
of HIV/AIDS annual per-patient drug costs of $500 for
patients not experiencing virological failure (NVF) and
$1,000 for patients that do experience virological failure
(VF). The rate of virological failure has been reported to
range between 21.7% and 82.1% depending on compli-
ance rates ranging between 95% and 70%. Thus, we var-
ied the compliance rate to determine the associated impact
on virological failure and drug costs. We also conducted
sensitivity analyses on drug prices.
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RESULTS: Varying the compliance rates between 95% and
70% resulted in the average annual drug costs per patient
ranging between $609 and $911 (49.6% difference). Sensi-
tivity analyses of published drug-cost ranges between $400
and $821 for NVF and $800 and $1642 for VF caused av-
erage annual drug costs to vary by 51.8%. Reexamining the
94% compliance assumptions of a recently published report
found that the $1.1 billion estimate for treating HIV/AIDS
in Africa may underestimate costs by more than 28%.
CONCLUSION: Given that studies have demonstrated a
high degree of variability in HIV/AIDS drug compliance
in Africa, future cost studies should examine the impact
of varying compliance rates on their results.
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OBJECTIVE: To outline results of a retrospective analysis
of patient charts at three dermatology clinics in the Neth-
erlands for treatment of external genital warts (EGWs).
METHODS: Patient records with a principal treatment
of EGW were identified. A total of 530 completed epi-
sodes of care for EGWs were analyzed. A (completed) ep-
isode of care was defined as a sequence of visits resulting
in either wart clearance or patient referral to additional
care, typically surgery.
RESULTS: Over 80% of the patients were initially treated
with monotherapy, and podophyllin and cryotherapy were
the principal initial therapy choices. Only 61.7% of males
and 68.4% of females completed an episode of care with
their initial choice of monotherapy. The average total cost of
an episode of care was DFL487.76 and DFL644.13 for males
and females respectively. The cost of achieving a successful
outcome or episode of care (taking into account the propor-
tion of patients with complete and incomplete episode of
care) was DFL872.50 for males and DFL1,068.91 for fe-
males. The cost of completing an episode of care for those
who initiated on podophyllin, taking into account therapy
switching, was DFL451.40 for males (DFL851.48 for fe-
males) compared with DFL426.63 for males initiated on
cryotherapy (DFL372.94 for females) and DFL780.56 for
males initiated on podophyllotoxin (DFL518.57 for females).
CONCLUSION: Podophyllin, although no longer recom-
mended in treatment guidelines, is one of the most fre-
quently used therapies. Costs of treating EGWs are sig-
nificantly impacted by the need to switch.
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OBJECTIVE: To estimate the cost-utility of universal vac-
cination of infants with four doses of a combined 9-valent
conjugated pneumococcal/6-valent outer membrane vesi-
cle meningococcal B/C vaccine in the Netherlands, from a
societal perspective.
METHODS: A decision analysis model is employed to
estimate the health outcomes and costs of the vaccination
program. Data were derived from the Netherlands Refer-
ence Laboratory for Bacterial Meningitis, PRISMANT
Healthcare, national and international literature, and an
expert panel. Direct costs and productivity costs (friction
cost method) are considered. Future costs and QALYs
are discounted at 4%. Cost-utility is expressed as net
costs (in 1998 €) per QALY gained. For the baseline, a
vaccine dose price of €20 and vaccine dose administra-
tion cost of €5 are assumed. The study fully corresponds
with the Dutch guidelines for pharmacoeconomic re-
search.
RESULTS: The vaccination program is estimated to cost
ED18,741,600, to prevent 27 deaths and 16 severe se-
quelae (e.g. seizures, spasticity, and mental retardation),
and to avoid €7,546,600 in expenses per year. It would
render 735 QALYs per year at a cost-utility of €15,200
per QALY. The break-even dose price of the vaccine is
€5.7. These results are sensitive to the vaccine price, the
vaccine effectiveness, and the vaccine coverage against
other meningococcal serosubtypes and pneumococcal se-
rotypes. Excluding the productivity costs has a limited in-
fluence.
CONCLUSIONS: The combination vaccine has not only
a favourable cost-utility ratio when compared to other
vaccines, but also averts a significant number of deaths
and severe sequelae. Therefore it would be a promising
candidate for national immunization programs.
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Clinical trial cost modeling is rarely done, but early pro-
tocol development and cost identification may reduce the
uncertainty surrounding return on investment for thera-
pies such as a new pulmonary TB drug.
OBJECTIVE: To develop a Phase III trial protocol for a po-
tential new pulmonary TB drug and estimate the trial costs.
METHODS: We developed a trial protocol based on the
study design submitted to the Food and Drug Administra-
